0.13
-1.52%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About INOVIQ
Its shares trade on ASX under the ticker IIQ.AX. It has been listed since 18 April 1991. In the fiscal year to 30 June 2026, it reported revenue of A$432,047 and a net loss of A$7.5m. At that date it held total assets of A$20.5m and shareholders' equity of A$18.9m.
INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. The firm has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. The Company’s cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. The company is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 18 Apr 1991
- Website
- inoviq.com ↗
Leadership
Pay as last reported
- Mr. David WilliamsNon-Executive Chairman of the Board
- Dr. Leearne HinchChief Executive OfficerA$485,322
- Mr. Mark EdwardsChief Financial Officer, Company Secretary
- Prof. Greg RiceChief Scientific OfficerA$252,853
- Mr. Geoffrey CummingNon-Executive DirectorA$137,946
- Ms. Mary HarneyNon-Executive Director
- Mr. Robert JohnstonNon-Executive DirectorA$110,446
- Mr. Philip PowellNon-Executive DirectorA$110,446
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- INOVIQ Ltd. offers hTERT ICC test for bladder cancer risk detection in cytopathology samples.
- The EXO-NET Pan-Exosome tool isolates exosomes from plasma, urine, and saliva for research use.
- INOVIQ's cancer diagnostic pipeline develops blood tests for early detection of ovarian, breast, and prostate cancers.
Weaknesses
- The hTERT ICC test is limited to adjunct use with urine cytology for bladder cancer risk assessment.
- EXO-NET is restricted to research use only (RUO) without regulatory approval for clinical use.
- INOVIQ's pipeline focuses on blood tests for cancer detection without current commercial products.
Opportunities
- Expanding the hTERT ICC test to additional cancer types beyond bladder cancer could increase market reach.
- Developing regulatory-approved versions of EXO-NET for clinical diagnostics may open new revenue streams.
- INOVIQ can leverage its pipeline to partner with healthcare providers for early cancer detection programs.
Threats
- Regulatory delays in approving blood tests for cancer detection could slow product commercialization.
- Competition from established diagnostic companies may limit market share for new blood tests.
- The reliance on research use only tools like EXO-NET poses a risk if clinical demand shifts away from RUO products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.